A Prospective Multicenter Phase 2 Study of Dose-Adjusted-EPOCH-R in Untreated MYC-Rearranged Aggressive B-cell Lymphoma

Corresponding Author: Wyndham H. Wilson, M.D., Ph.D., Lymphoid Malignancies Branch, CCR, NCI, Building 10, Room 4N115, National Institutes of Health, Bethesda, MD 20892. Office: 301-435-2415, Fax: 301-480-1105, wilsonw@mail.nih.gov. AUTHOR CONTRIBUTIONS Conception and design: Wyndham H. Wilson, Kieron Dunleavy, Richard F. Little. Provision of study materials or patients: All authors. Collection and assembly of data: All authors. Data analysis and interpretation: Primary is Wyndham Wilson and Seth Steinberg; All authors reviewed the analysis and provided comments and approval. Manuscript writing: All authors. No medical writer was used. Final approval of manuscript: All authors Accountable for all aspects of the work: Primary Wyndham Wilson and all authors *Full Professors or Equivalent

[1]  Philipp W. Raess,et al.  Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma , 2018, Leukemia & lymphoma.

[2]  A. Rosenwald,et al.  High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. , 2018, Blood.

[3]  J. Cerhan,et al.  Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Roland Schmitz,et al.  Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.

[5]  W. Wilson,et al.  MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R , 2018, Leukemia & lymphoma.

[6]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[7]  J. Friedberg.  How I treat double-hit lymphoma. , 2017, Blood.

[8]  J. Vose,et al.  Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Rosenwald,et al.  Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  W. Wilson,et al.  Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. , 2016, Journal of the National Cancer Institute.

[11]  Scott E. Smith,et al.  Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable , 2016, British journal of haematology.

[12]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[13]  L. Medeiros,et al.  B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas , 2015, Modern Pathology.

[14]  Scott E. Smith,et al.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. , 2014, Blood.

[15]  Michael L. Wang,et al.  Double hit lymphoma: the MD Anderson Cancer Center clinical experience , 2014, British journal of haematology.

[16]  David Cunningham,et al.  Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles , 2013, The Lancet.

[17]  J. Friedberg.  Double-hit diffuse large B-cell lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  W. Wilson,et al.  A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype , 2012, Haematologica.

[19]  Philip M Kluin,et al.  Double-hit B-cell lymphomas. , 2011, Blood.

[20]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[22]  I. Miura,et al.  Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations , 2009, Leukemia.

[23]  L. Staudt,et al.  Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. Wilson,et al.  High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. , 2005, Blood.

[26]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[27]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.